本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 证券代码：688617 证券简称：惠泰医疗 公告编号：2026-006 深圳惠泰医疗器械股份有限公司 关于以集中竞价方式首次回购股份的公告 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次实施回购股份情况公告如下： 2026 年 2 月 11 日，公司通过集中竞价交易方式首次回购公司股份 77,000 股， 占公司总股本 141,030,049 股的比例约为 0.05%，回购成交的最高价为 242.27 元/ 股，最低价为 241.00 元/股，支付的资金总额为人民币 18,605,600.00 元（不含印花 税、交易佣金等交易费用）。 本次回购股份符合相关法律法规及公司回购股份方案的规定。 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2026/2/10，由董事会提议 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2026 年 2 月 9 12 月 8 | ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-005 二、公司前十名无限售条件股东持股情况 | 序号 | 股东名称 | 持股数量（股） | 占公司总股 | | --- | --- | --- | --- | | | | | 本比例（%） | | 1 | 深圳迈瑞科技控股有限责任公司 | 32,508,228 | 23.05 | | 2 | 成正辉 | 23,551,232 | 16.70 | | 3 | 香港中央结算有限公司 | 8,380,590 | 5.94 | | 4 | 珠海彤昇投资合伙企业（有限合伙） | 4,909,960 | 3.48 | | 5 | 招商银行股份有限公司－华夏上证科创板 | 50 3,188,292 | 2.26 | | | 成份交易型开放式指数证券投资基金 | | | | 6 | 中国银行股份有限公司－华宝中证医疗交易 | 2,577,144 | 1.83 | | | 型开放式指数证券投资基金 | | | | 7 | 徐轶青 | 2,520,320 | 1.79 | | 8 | 中国银行股份有限公司－易方达蓝筹精选混 | 2,500,000 | 1.77 | ...

Group 1 - On February 10, brokerages set target prices for listed companies with notable increases for Kehua Data, Nanwei Medical, and Fulete, with target price increases of 19.70%, 18.54%, and 14.09% respectively, belonging to the other power equipment, medical devices, and photovoltaic equipment industries [1][3] - A total of 21 listed companies received brokerage recommendations on February 10, with companies like Bailong Oriental, Chiplink Integration, and Tianrun Industrial each receiving one recommendation [3] - One company, Haomai Technology, had its rating upgraded from "Hold" to "Buy" by Guotou Securities on February 10 [4][5] Group 2 - Three companies received initial coverage on February 10, including Xin'ao Co., which was rated "Buy" by Shenda Securities, Bichu Electronics rated "Increase" by Jianghai Securities, and Huitai Medical rated "Buy" by Huayuan Securities [5][6] - The companies receiving initial coverage are in the textile manufacturing, computer equipment, and medical device industries [6]

Core Viewpoint - The China Securities Medical Index (399989) closed at 7197.66 points on February 10, with a 0.5% increase and a trading volume of 19.639 billion yuan, indicating a stable performance in the medical sector [1]. Group 1: Index Performance - The index saw 25 constituent stocks rise, with Huitai Medical leading the gains at 5.15%, while 24 stocks declined, with Huaxi Biological leading the losses at 3.36% [1]. - The turnover rate for the index was 1.82%, reflecting moderate trading activity [1]. Group 2: Capital Flow - The net inflow of main funds into the constituent stocks of the index totaled 554 million yuan, indicating positive institutional interest [2]. - Retail investors experienced a net outflow of 416 million yuan, suggesting a cautious sentiment among individual investors [2]. - Speculative funds saw a net outflow of 159 million yuan, indicating reduced trading activity from this segment [2].

Group 1: Autonomous Mining Trucks - The report highlights the potential of the autonomous mining truck sector, citing it as one of the fastest-growing areas for large-scale commercialization of autonomous driving, with a high market ceiling [2][7] - The technology is mature and economically viable, supported by policies encouraging automation in hazardous environments, and the competitive landscape is establishing high industry barriers [2][7] - The market size for the product model of autonomous mining trucks is estimated to exceed 20 billion yuan in the medium to long term, with advantages such as asset-light operations and quick payment cycles for service providers [2][7] Group 2: Swine Industry - The report discusses the ongoing decline in pig prices, with the central government's emphasis on comprehensive capacity regulation as outlined in the No. 1 Central Document [10][11] - The swine breeding sector is experiencing a gradual recovery, with expectations of a price rebound post-Spring Festival, driven by cost reductions and improved profitability [10][11] - The report recommends focusing on leading companies in the swine breeding sector, such as Muyuan Foods and Wens Foodstuffs, which are expected to benefit from the evolving regulatory landscape [10][11] Group 3: Medical Sector - Huitai Medical - Huitai Medical is positioned as a leading manufacturer in electrophysiology and vascular intervention, with a focus on coronary access and heart electrophysiology [18][19] - The market for PFA devices is projected to reach 16.315 billion yuan by 2032, with a compound annual growth rate of 43.73% from 2025 to 2032, indicating significant growth potential [19][21] - The company is expected to enhance its competitive edge through product diversification and capacity expansion, with revenue forecasts showing substantial growth from 2.578 billion yuan in 2025 to 4.060 billion yuan in 2027 [21]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook based on the rapid growth of its PFA products and increasing competitiveness in the electrophysiology and vascular intervention sectors [5][9]. Core Insights - The company is expected to achieve total revenues of RMB 25.78 billion, RMB 32.40 billion, and RMB 40.60 billion for the years 2025 to 2027, with growth rates of 24.78%, 25.70%, and 25.31% respectively. The net profit attributable to shareholders is projected to be RMB 8.34 billion, RMB 10.57 billion, and RMB 13.40 billion for the same years, with growth rates of 23.95%, 26.73%, and 26.70% respectively [6][9]. - The company has a strong position in the cardiovascular intervention field, with a comprehensive product layout that includes electrophysiology and vascular intervention devices. The introduction of new PFA products is expected to drive significant revenue growth [11][15]. Summary by Sections Market Performance - The closing price of the company's stock is RMB 229.38, with a market capitalization of RMB 32,349.47 million. The stock has seen a yearly high of RMB 466.07 and a low of RMB 223.48 [3]. Financial Forecasts - The company anticipates revenue growth from RMB 1,650 million in 2023 to RMB 4,060 million in 2027, with a compound annual growth rate (CAGR) of 35.71% from 2023 to 2024 and 25.31% from 2025 to 2027. Net profit is expected to grow from RMB 534 million in 2023 to RMB 1,340 million in 2027, with a CAGR of 49.13% from 2023 to 2024 and 26.70% from 2025 to 2027 [7][9]. Business Overview - The company has established itself as a leading manufacturer in the domestic electrophysiology and vascular intervention market, focusing on coronary access and cardiac electrophysiology. The introduction of PFA products is expected to enhance its competitive edge [8][15]. - The company has successfully participated in domestic alliance procurement, securing a significant market share in coronary access products, which now account for nearly 90% of its offerings [8][11]. Growth Drivers - The increasing prevalence of atrial fibrillation due to an aging population is expected to drive demand for PFA devices, with the market projected to reach RMB 163.15 billion by 2032, growing at a CAGR of 43.73% from 2025 to 2032 [8][59]. - The company has completed over 2,000 PFA procedures by August 2025, indicating strong market acceptance and growth potential for its new products [78]. Competitive Landscape - The domestic electrophysiology market is currently dominated by foreign brands, but the company is positioned to capture market share through competitive pricing and product quality improvements following recent procurement agreements [63][70].

Core Viewpoint - The company Huatai Medical (688617) announced a share buyback plan to enhance investor confidence and establish a long-term incentive mechanism, with a total buyback amount between 150 million and 200 million yuan, at a maximum price of 315 yuan per share [1] Group 1: Buyback Plan - The buyback will be conducted through centralized bidding and is expected to occur within 10 months from the board's approval [1] - The estimated number of shares to be repurchased ranges from 476,200 to 634,900, representing 0.34% to 0.45% of the company's total share capital [1] - The company stated that the buyback will not significantly impact its daily operations, finances, research and development, or future growth [1] Group 2: Company Performance - Huatai Medical specializes in the research, production, and sales of electrophysiological and interventional medical devices, focusing on coronary pathways and cardiac electrophysiology [1] - For the first three quarters of 2025, the company reported total operating revenue of 1.867 billion yuan, a year-on-year increase of 22.47%, and a net profit attributable to shareholders of 623 million yuan, up 18.02% year-on-year [1]

Core Viewpoint - The financial performance of Huitai Medical (688617) shows significant growth in revenue and net profit, indicating a strong position in the medical device industry focused on electrophysiology and vascular intervention [3]. Financial Performance - For the first three quarters of 2025, Huitai Medical reported a main revenue of 1.867 billion yuan, a year-on-year increase of 22.47% [3]. - The net profit attributable to shareholders reached 623 million yuan, up 18.02% year-on-year [3]. - The third quarter alone saw a main revenue of 654 million yuan, reflecting a 24.77% increase compared to the same quarter last year [3]. - The net profit for the third quarter was 198 million yuan, with a year-on-year growth of 6.77% [3]. - The company maintained a gross profit margin of 73.19% [3]. Financing and Trading Activity - On February 9, 2026, Huitai Medical's stock closed at 229.38 yuan, with a trading volume of 7315 hands and a total transaction amount of 167 million yuan [1]. - The net inflow of main funds was 12.89 million yuan, accounting for 7.71% of the total transaction amount, while retail investors saw a net outflow of 1.67 million yuan [1]. - The financing data indicated a net financing purchase of 3.12 million yuan on the same day, with a total financing balance of 181 million yuan [2]. Institutional Ratings - In the last 90 days, four institutions provided ratings for Huitai Medical, with three giving a "buy" rating and one an "increase" rating [4].

Core Viewpoint - Shenzhen Huatai Medical Devices Co., Ltd. has announced a share repurchase plan aimed at enhancing investor confidence and establishing a long-term incentive mechanism for sustainable development [1][5]. Group 1: Share Repurchase Plan - The total amount for the share repurchase will not be less than RMB 150 million and not exceed RMB 200 million [6]. - The source of funds for the repurchase will be the company's own funds [7]. - The repurchased shares will be used for employee stock ownership plans or equity incentives within three years after the announcement of the repurchase results [7][26]. Group 2: Repurchase Details - The maximum repurchase price is set at RMB 315 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [8][19]. - The repurchase will be conducted through the Shanghai Stock Exchange via centralized bidding [8][14]. - The repurchase period is set for 10 months from the board's approval date [9][15]. Group 3: Voting and Approval - The board meeting held on February 9, 2026, had all 9 directors present, with a unanimous vote of 9 in favor, 0 against, and 0 abstentions [3][12]. - The repurchase plan does not require shareholder approval as per the company's articles of association [12]. Group 4: Financial Impact - As of September 30, 2025, the company's total assets were approximately RMB 3.46 billion, and the equity attributable to shareholders was about RMB 2.99 billion [22]. - The planned repurchase amount represents approximately 5.78% of total assets and 6.69% of equity [22]. Group 5: Shareholder Actions - The company’s major shareholders, including directors and senior management, have no clear plans for share reduction in the next three to six months following the board's decision [10][24].

Core Viewpoint - Shenzhen Huitai Medical Equipment Co., Ltd. has approved a share repurchase plan to enhance investor confidence and establish a long-term incentive mechanism [1] Group 1: Share Repurchase Plan - The company plans to use its own funds to repurchase part of its A-shares through centralized bidding, with a total repurchase amount not less than RMB 150 million and not exceeding RMB 200 million [1] - The maximum repurchase price is set at RMB 315 per share, and the repurchase period is within 10 months from the board's approval date [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives, and if not fully transferred within three years, they will be legally canceled [1] Group 2: Financial Position - As of September 30, 2025, the company's total assets are approximately RMB 3.461 billion, and the net assets attributable to shareholders are about RMB 2.989 billion [1] - Based on the upper limit of the repurchase funds, the repurchase amount accounts for approximately 6.69% of the net assets [1] Group 3: Impact and Confidence - The company believes that the repurchase will not significantly impact its daily operations, finances, or future development, nor will it lead to a change in control or affect its listing status [1] - The decision is based on confidence in the industry outlook and the company's future development [1]